SCHEMBL13833705

SCHEMBL13833705

CCN1CCc2c(oc(N)c2-c2nc3ccccc3s2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.49
▸ ILK Q13418 8/20 0.48
▸ RAB9A P51151 4/20 0.43
▸ NPC1 O15118 4/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ KDM4E B2RXH2 7/20 0.43
▸ HPGD P15428 3/20 0.43
▸ MAPT P10636 5/20 0.41
▸ ALDH1A1 P00352 5/20 0.41
▸ HRH3 Q9Y5N1 1/20 0.41
▸ APEX1 P27695 2/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ HTT P42858 1/20 0.41
▸ DRD2 P14416 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13833712 0.81 LMNA (0.55) LMNARAB9ANPC1POLBKDM4E
SCHEMBL13833586 0.81 LMNA (0.60) LMNAILKRAB9ANPC1SMN1; SMN2
SCHEMBL13833699 0.79 LMNA (0.55) LMNARAB9ANPC1SMN1; SMN2POLB
SCHEMBL13833639 0.74 LMNA (0.63) LMNARAB9ANPC1SMN1; SMN2POLB
SCHEMBL13833602 0.74 LMNA (0.70) LMNARAB9ANPC1POLBKDM4E
SCHEMBL18282019 0.73 APEX1 (0.58) LMNAILKRAB9ANPC1SMN1; SMN2
SCHEMBL13833669 0.73 LMNA (0.66) LMNARAB9ANPC1POLBKDM4E
SCHEMBL13833590 0.71 APEX1 (0.77) LMNARAB9ANPC1POLBKDM4E
SCHEMBL13833641 0.71 LMNA (0.63) LMNARAB9ANPC1SMN1; SMN2POLB
Hydrochloric Acid SCHEMBL14777279 0.70 APEX1 (0.76) LMNARAB9ANPC1POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. 2013-03-21 — — US disclosed
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. 2013-03-21 — — US disclosed
WO-2012154888-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. (US) 2012-11-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS HSPA5, PSMG3, VCP LMNA 481/4885ILK 2762/4885RAB9A 858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback